Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Tabelecleucel in the treatment of EBV+ PTLD

AJ Joshi • 22 Dec 2021
ASH 2021
Antibodies CAR-T Rituximab Tabelecleucel

In this video, AJ Joshi, MD, Atara Biotherapeutics, San Francisco, CA, presents some data on a study which aimed to investigate the use of tabelecleucel, a targeted T-cell therapy, in patients with Epstein-Barr positive post-transplant lymphoproliferative disorder (EBV+ PTLD). Dr Joshi first gives some background information on the disease biology and current treatment options for EBV+ PTLD, drawing focus on the use of rituximab. Dr Joshi then discusses the results from this study, including the overall response rate, durability of response, and overall survival observed in patients treated with tabelecleucel. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.

More from AJ Joshi

2:35
Tabelecleucel as an alternative treatment option in patients following transplantation
AJ Joshi • 22 Dec 2021
The content of VJHemOnc is intended for healthcare professionals